Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR-PI3K: Alpelisib + Fulvestrant in PIK3CA+ Breast Cancer
NCT03386162Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Mar 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Unicancer. Started Mar 2018; status: terminated.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03386162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386162.